Diabetes & Metabolic Syndrome-Clinical Research & Reviews最新文献_第7页

Response to the Letter to the Editor regarding “Global research trends and hotspots in gestational diabetes and long-term cardiovascular health: A bibliometric analysis.” 关于“妊娠糖尿病和长期心血管健康的全球研究趋势和热点：文献计量学分析”的致编辑信的回复。

IF 4.3

Diabetes & Metabolic Syndrome-Clinical Research & Reviews Pub Date : 2025-02-01 DOI: 10.1016/j.dsx.2025.103191

Yanxi Jia , Qing Hu , Hua Liao , Hongyan Liu , Zhaomin Zeng , Haiyan Yu

引用次数: 0

Digital technologies for prediabetes: A systematic review and meta-analysis 数字技术治疗前驱糖尿病：系统回顾和荟萃分析

IF 4.3

Diabetes & Metabolic Syndrome-Clinical Research & Reviews Pub Date : 2025-02-01 DOI: 10.1016/j.dsx.2025.103206

Choon Ming Ng, Wing Loong Cheong, Chun Wie Chong, Siew Li Teoh, Wuan Shuen Yap, Shaun Wen Huey Lee

引用次数: 0

Effects of deep ocean-derived magnesium-enhanced water on metabolic diseases with microbiome changes 深海来源的镁强化水对微生物组变化的代谢性疾病的影响

IF 4.3

Diabetes & Metabolic Syndrome-Clinical Research & Reviews Pub Date : 2025-02-01 DOI: 10.1016/j.dsx.2025.103203

Huiwon Kang , Un Jae Lee , Bum Yong Park , Minju Kim , Mihi Yang

{"title":"Effects of deep ocean-derived magnesium-enhanced water on metabolic diseases with microbiome changes","authors":"Huiwon Kang , Un Jae Lee , Bum Yong Park , Minju Kim , Mihi Yang","doi":"10.1016/j.dsx.2025.103203","DOIUrl":"10.1016/j.dsx.2025.103203","url":null,"abstract":"<div><h3>Aims</h3><div>To investigate the effects of magnesium (Mg) from deep ocean sources, we conducted a randomized clinical trial involving adults with hypertension, diabetes, or hyperlipidemia.</div></div><div><h3>Methods</h3><div>Subjects consumed either Mg-enriched water (MEW) or a placebo (80 or 6 mg of Mg per 2 L/day, respectively) for 4 weeks. We examined the detoxifying effects of MEW on environmental toxicants, including polycyclic aromatic hydrocarbons (PAHs) and oxidative stress, and its impact on gut microbiome composition (N = 30; 49.26 ± 9.55 yrs).</div></div><div><h3>Results</h3><div>Most subjects consumed less Mg than the RDA, enabling their participation in the trial. Despite limitations in serum Mg measurement to assess Mg intake, MEW intake led to improvements in body mass index (BMI), insulin levels, triglycerides, glucose-BMI, and fatigue. Regardless of Mg content, water consumption reduced urinary levels of 1-hydroxypyrene, a major PAH metabolite, and malondialdehyde, an oxidative stress biomarker. Moreover, the MEW group exhibited greater diversity in gut microbiome composition than the placebo group. Notably, MEW kept the abundance of <em>Clostridium</em>, <em>Dorea</em>, or <em>Desulfovibrio</em>, indicating a balanced Mg intake.</div></div><div><h3>Conclusion</h3><div>MEW (80 mg of Mg/day) appears safe for RDA and effective for preventing CVD or T2DM, as evidenced by gut microbiome and biomarker outcomes.</div></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"19 2","pages":"Article 103203"},"PeriodicalIF":4.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143396057","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The role of melatonin and circadian rhythms in the pathogenesis of diabetic retinopathy: A systematic review 褪黑激素和昼夜节律在糖尿病视网膜病变发病机制中的作用：一项系统综述

IF 4.3

Diabetes & Metabolic Syndrome-Clinical Research & Reviews Pub Date : 2025-02-01 DOI: 10.1016/j.dsx.2025.103202

Mallika Prem Senthil , Eilish Devlin , Abolfazl Hassani, Eugene Lee, Royston Yi Sheng An, Steven Oh, Joshua Barclay, Muhammad Husnain, Jose J. Estevez, Ranjay Chakraborty

{"title":"The role of melatonin and circadian rhythms in the pathogenesis of diabetic retinopathy: A systematic review","authors":"Mallika Prem Senthil , Eilish Devlin , Abolfazl Hassani, Eugene Lee, Royston Yi Sheng An, Steven Oh, Joshua Barclay, Muhammad Husnain, Jose J. Estevez, Ranjay Chakraborty","doi":"10.1016/j.dsx.2025.103202","DOIUrl":"10.1016/j.dsx.2025.103202","url":null,"abstract":"<div><h3>Aims</h3><div>This review investigates literature on systemic melatonin levels and circadian timing in diabetic retinopathy (DR), examining their associations with DR.</div></div><div><h3>Methods</h3><div>Our search was conducted in March 14, 2024, and included the databases Medline, Web of Science, Scopus, ProQuest Health, Latin American and Caribbean Health Sciences Literature (LILACS), Cochrane, International Standard Randomised Controlled Trial Number (ISRCTN) registry, and International Clinical Trials Registry Platform (ICTRP).</div></div><div><h3>Results</h3><div>Our review analysed twelve articles measuring melatonin concentration in saliva, blood serum, urine, or aqueous humour. Studies measuring melatonin levels in saliva found no significant differences in the average nocturnal or daytime melatonin levels between type 2 diabetes (T2D) patients with and without DR. The studies comparing serum melatonin levels in patients with different stages of DR and controls showed inconsistent results. Only two studies measured the endogenous onset of melatonin secretion, known as dim light melatonin onset (DLMO), a highly accurate biomarker for circadian regulation. These studies showed that only 33% and 57% of patients with DR had detectable DLMO in saliva and serum, respectively. All studies evaluating overnight melatonin production using urinary aMT6s (urinary 6-sulfaoxymelatonin) levels found that DR was associated with lower nocturnal melatonin production.</div></div><div><h3>Conclusions</h3><div>Our review results showed evidence of reduced nocturnal melatoin production in DR with no significant changes in melatonin circadian timing.</div></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"19 2","pages":"Article 103202"},"PeriodicalIF":4.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143376541","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Agreement and disagreement between diagnostic criteria for gestational diabetes and implications for clinical practice: A retrospective observational study 妊娠期糖尿病诊断标准的一致和不一致及其对临床实践的影响：一项回顾性观察研究

IF 4.3

Diabetes & Metabolic Syndrome-Clinical Research & Reviews Pub Date : 2025-02-01 DOI: 10.1016/j.dsx.2025.103207

Alpesh Goyal , Rahul Gupta , Avantika Gupta , Astha Yadav , Ashish Jadhav , Rekha Singh

{"title":"Agreement and disagreement between diagnostic criteria for gestational diabetes and implications for clinical practice: A retrospective observational study","authors":"Alpesh Goyal , Rahul Gupta , Avantika Gupta , Astha Yadav , Ashish Jadhav , Rekha Singh","doi":"10.1016/j.dsx.2025.103207","DOIUrl":"10.1016/j.dsx.2025.103207","url":null,"abstract":"<div><h3>Aims</h3><div>To evaluate agreement/disagreement between eleven gestational diabetes (GDM) diagnostic criteria, including five used in current clinical practice globally.</div></div><div><h3>Methods</h3><div>Records of 353 pregnant women with oral glucose tolerance test performed after 20 weeks of gestation were retrospectively reviewed. The diagnosis of GDM was compared using the IADPSG, DIPSI, WHO 1999, CDA 2003 and 2013, NICE 2015, JSOG 1984, ADIPS 1998, ADA 2004, NZSSD 2004 and EASD 1996 criteria. The agreement between criteria was expressed as Cohen's kappa coefficient (k; 0.4–0.6, moderate; 0.6–0.8, good; 0.8–1.0, very good) and disagreement as percentage (d). IADPSG criteria were used as a reference for comparison.</div></div><div><h3>Results</h3><div>The prevalence of GDM varied from 7.4 % (95 % CI, 4.9–10.4 %) by CDA 2003 criteria to 23.8 % (95 % CI, 19.5–28.4 %) by IADPSG criteria. Of the 55 pair-wise criteria comparisons, 29 (52.7 %) showed moderate, 16 (29.1 %) good, and 10 (18.2 %) very good agreement. Among the currently used criteria, the CDA 2013 (k = 0.811; d = 6.2 %) agreed the most, the DIPSI/WHO 1999 (k = 0.456) agreed the least, and the NICE 2015 (k = 0.580) criteria showed an intermediate agreement with the IADPSG criteria.</div></div><div><h3>Conclusions</h3><div>There is a marked variation in the prevalence of GDM, with a significant degree of disagreement between different diagnostic criteria. The study findings should be interpreted in the context of its retrospective nature and non-consecutive recruitment, which introduce a potential for selection bias.</div></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"19 2","pages":"Article 103207"},"PeriodicalIF":4.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143444822","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Ahmedabad declaration: A framework to combat growing epidemic of young-onset type 2 diabetes in Asia 艾哈迈达巴德宣言：在亚洲对抗日益流行的年轻型2型糖尿病的框架

IF 4.3

Diabetes & Metabolic Syndrome-Clinical Research & Reviews Pub Date : 2025-02-01 DOI: 10.1016/j.dsx.2025.103205

Rakesh.M. Parikh , Banshi Saboo , Anoop Misra , Abdul Basit , S.R. Aravind , Bishwajit Bhowmik , Peter Schwarz , Ketan Dhatariya , Kamlesh Khunti , Shashank Joshi , Sunil Gupta , Amit Gupta , Manoj Chawla , Sanjeev Phatak , Sanjay Kalra , Azad Khan , Viswanathan Mohan

{"title":"Ahmedabad declaration: A framework to combat growing epidemic of young-onset type 2 diabetes in Asia","authors":"Rakesh.M. Parikh , Banshi Saboo , Anoop Misra , Abdul Basit , S.R. Aravind , Bishwajit Bhowmik , Peter Schwarz , Ketan Dhatariya , Kamlesh Khunti , Shashank Joshi , Sunil Gupta , Amit Gupta , Manoj Chawla , Sanjeev Phatak , Sanjay Kalra , Azad Khan , Viswanathan Mohan","doi":"10.1016/j.dsx.2025.103205","DOIUrl":"10.1016/j.dsx.2025.103205","url":null,"abstract":"<div><h3>Aim</h3><div>Rising prevalence of Type 2 Diabetes (T2D) among young Asians has emerged as a public health crisis that threatens the long-term health, economic stability, and productivity of nations across Asia (1). Early-onset T2D poses unique challenges, including higher rates of undiagnosed cases, more aggressive disease progression, an increased risk of chronic complications and higher mortality (2). Hyperglycemia during the reproductive age especially among the female population can potentially have transgenerational impact through epigenetic changes.</div></div><div><h3>Methods</h3><div>A comprehensive search was conducted on PubMed with a combination of relevant keywords. A preliminary draft prepared after review of literature was electronically circulated among a panel of 64 experts from various parts of the region and representatives of the participating organizations - Diabetes India (<span><span>www.diabetesindia.org.in</span><svg><path></path></svg></span>) and the Diabetes Asia Study Group (DASG, <span><span>www.da-sg.org</span><svg><path></path></svg></span>).</div></div><div><h3>Results</h3><div>This Ahmedabad Declaration outlines the scale of the problem, its root causes, and a comprehensive action plan for Asian populations. The objectives of this declaration include raising awareness, addressing systemic barriers, and advocating for evidence-based policies and interventions, limited to people with T2D. Through collaborative efforts, we aim to mitigate the growing burden of diabetes in young Asians and secure a healthier future.</div></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"19 2","pages":"Article 103205"},"PeriodicalIF":4.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143548585","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Highlights of the current issue 当前问题的重点

IF 4.3

Diabetes & Metabolic Syndrome-Clinical Research & Reviews Pub Date : 2025-01-01 DOI: 10.1016/j.dsx.2025.103192

Ningjian Wang (Associate Editor) , Anoop Misra (Editor-in-Chief)

引用次数: 0

The effects of prune products consumption on anthropometric measurements and blood pressure in adults: A systematic review and dose-response meta-analysis 西梅制品消费对成人人体测量和血压的影响：一项系统评价和剂量反应荟萃分析。

IF 4.3

Diabetes & Metabolic Syndrome-Clinical Research & Reviews Pub Date : 2025-01-01 DOI: 10.1016/j.dsx.2024.103173

Azadeh Heydarian , Shima Moradi , Omid Asbaghi , Negin Tahvilian , Sahar Cheshmeh , Maryam Nadery , Naheed Aryaeian

{"title":"The effects of prune products consumption on anthropometric measurements and blood pressure in adults: A systematic review and dose-response meta-analysis","authors":"Azadeh Heydarian , Shima Moradi , Omid Asbaghi , Negin Tahvilian , Sahar Cheshmeh , Maryam Nadery , Naheed Aryaeian","doi":"10.1016/j.dsx.2024.103173","DOIUrl":"10.1016/j.dsx.2024.103173","url":null,"abstract":"<div><h3>Introduction</h3><div>The positive impact of prunes on body measurements and blood pressure has been suggested in previous research.</div></div><div><h3>Purpose</h3><div>The purpose of this extensive meta-analysis and systematic review was to examine the effects of adult consumption of prunes on anthropometric parameters and blood pressure.</div></div><div><h3>Methods</h3><div>To identify relevant randomized controlled trials (RCTs) (till August 9th, 2024), databases from ISI Web of Science, Scopus, and PubMed/Medline were searched. The current systematic review and meta-analysis covered 14 studies that met the eligibility requirements. The weighted mean difference was used to compute the effect size. The Cochrane Q test and I2 index were used to measure study heterogeneity. The random effects model was utilized to get the overall effect magnitude.</div></div><div><h3>Results</h3><div>The meta-findings analysis's showed that eating prunes had no appreciable effects on, body mass index (BMI) (p = 0.267), waist circumference (WC) (p = 0.562), fat mass (FM) (p = 0.840), systolic blood pressure (SBP) (p = 0.338), or diastolic blood pressure (DBP) (p = 0.233). However, we observed significantly reduction in body weight (p < 0.001) after prunes consumption.</div></div><div><h3>Conclusion</h3><div>Our findings showed that the consumption of prune leads to a significant reduction in body weight, but the results indicated non-significant effects on blood pressure, BMI, WC and FM.</div></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"19 1","pages":"Article 103173"},"PeriodicalIF":4.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142899297","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evaluating the causal effect of using glucagon-like peptide-1 receptor agonists on the risk of autoimmune diseases 评估使用胰高血糖素样肽-1受体激动剂对自身免疫性疾病风险的因果影响。

IF 4.3

Diabetes & Metabolic Syndrome-Clinical Research & Reviews Pub Date : 2025-01-01 DOI: 10.1016/j.dsx.2025.103186

Yuming Sun , Qian zhou , Lorraine Edna Onzere , Yating Dian , Yu Meng , Daishi Li , Furong Zeng , Shaorong Lei , Guangtong Deng

{"title":"Evaluating the causal effect of using glucagon-like peptide-1 receptor agonists on the risk of autoimmune diseases","authors":"Yuming Sun , Qian zhou , Lorraine Edna Onzere , Yating Dian , Yu Meng , Daishi Li , Furong Zeng , Shaorong Lei , Guangtong Deng","doi":"10.1016/j.dsx.2025.103186","DOIUrl":"10.1016/j.dsx.2025.103186","url":null,"abstract":"<div><h3>Objective</h3><div>To investigate the causal association of using glucagon-like peptide-1 receptor (GLP1R) agonists with autoimmune diseases.</div></div><div><h3>Methods</h3><div>The available cis-eQTLs for drugs target genes (GLP1R) were used as genetic variants for exposure to GLP1R agonists. Type 2 diabetes was used as positive control. Mendelian randomizations (MR) were performed to explore the association of genetically-proxied GLP1R agonists with 11 autoimmune diseases from large-scale consortia. Replicating the findings in the FinnGen study and then pooled with meta-analysis. Finally, we performed MR analysis to examine whether GLP1R agonists affect 731 immune cell phenotypes to clarify the potential mechanism.</div></div><div><h3>Results</h3><div>We observed supportive evidence to support the association of GLP1R agonists with reduced the risk of hypothyroidism (OR [95 %] = 0.89 [0.82–0.95], <em>P</em> < 0.001), but increased risk of ulcerative colitis (OR [95 %] = 1.48 [1.27–1.71], <em>P</em> < 0.001), type 1 diabetes (OR [95 %] = 1.34 [1.21–1.50], <em>P</em> < 0.001), systemic lupus erythematosus (OR [95 %] = 1.61 [1.29–2.02], <em>P</em> < 0.001) and sarcoidosis (OR [95 %] = 1.38 [1.08–1.75], <em>P</em> = 0.008). There was no supporting evidence to verify the association of GLP1R expression with asthma, Crohn's disease, multiple sclerosis and myasthenia gravis (<em>P</em> > 0.05). In addition, we found that GLP1R agonists was positively associated with 221 immune cell phenotypes (P < 0.05, OR > 1), and negatively associated with 317 immune cell phenotypes (P < 0.05, OR < 1).</div></div><div><h3>Conclusion</h3><div>GLP1R agonists are causally associated with various autoimmune diseases potentially through the modulation of 731 immune cell phenotypes.</div></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"19 1","pages":"Article 103186"},"PeriodicalIF":4.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142967086","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The predictive value of estimated glucose disposal rate for all-cause and cardiovascular mortality in the US non-diabetic population aged ≥60 years: A population-based cohort study 在美国年龄≥60岁的非糖尿病人群中，估计葡萄糖处置率对全因死亡率和心血管死亡率的预测价值：一项基于人群的队列研究

IF 4.3

Diabetes & Metabolic Syndrome-Clinical Research & Reviews Pub Date : 2025-01-01 DOI: 10.1016/j.dsx.2024.103182

Botao Zhu, Chenghui Cao, Wenwu Liu, Yuxuan Liu, Yonghong Luo, Daoquan Peng

{"title":"The predictive value of estimated glucose disposal rate for all-cause and cardiovascular mortality in the US non-diabetic population aged ≥60 years: A population-based cohort study","authors":"Botao Zhu, Chenghui Cao, Wenwu Liu, Yuxuan Liu, Yonghong Luo, Daoquan Peng","doi":"10.1016/j.dsx.2024.103182","DOIUrl":"10.1016/j.dsx.2024.103182","url":null,"abstract":"<div><h3>Aims</h3><div>This study seeks to evaluate the prognostic significance of eGDR in predicting mortality outcomes within non-diabetic older adults.</div></div><div><h3>Methods</h3><div>8131 non-diabetic participants aged ≥60 years from the National Health and Nutrition Examination Survey (2001–2018) was included in this study. eGDR was calculated as: eGDR (mg/kg/min) = 21.158 – [0.09 × waist circumference (cm)] – [3.407 × Hypertension (Yes = 1/No = 0)] – [0.551 × HbA1c (%)]. Weighted Cox proportional hazards models, cumulative hazard curves, restricted cubic spline (RCS), and threshold effects analyses were performed to explore the relationship between eGDR and mortality outcomes. Subgroup analyses and mediation effects analyses were conducted.</div></div><div><h3>Results</h3><div>2566 all-cause deaths and 689 cardiovascular deaths were recorded. Lower eGDR was associated with higher all-cause (HR = 0.76, 95 % CI: 0.63–0.91) and cardiovascular mortality (HR = 0.56, 95 % CI: 0.40–0.80). Inflection points were identified through RCS curve analyses, and the threshold effect was significant. The eGDR-mortality association remained consistent across subgroups. Mediation analyses showed that neutrophil to high-density lipoprotein cholesterol ratio mediated the association.</div></div><div><h3>Conclusions</h3><div>Lower eGDR levels are linked to higher risk of both all-cause and cardiovascular mortality in non-diabetic older adults, suggesting its potential utility for risk assessment among this population.</div></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"19 1","pages":"Article 103182"},"PeriodicalIF":4.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142899303","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0